Oshadi D - Oshadi Drug Administration

Drug Profile

Oshadi D - Oshadi Drug Administration

Alternative Names: DNase in Oshadi carrier

Latest Information Update: 04 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oshadi Drug Administration
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Basal cell cancer; Non-small cell lung cancer
  • No development reported Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 16 Apr 2018 Oshadi Drug Administration suspends patient enrolment in a phase I/IIa trial for Mesothelioma (Combination therapy) in Israel (NCT01627795)
  • 16 Apr 2018 Oshadi Drug Administration suspends patient enrolment in a phase II trial for Acute myeloid leukaemia andPrecursor cell lymphoblastic leukaemia lymphoma(Second-line therapy or greater, Combination therapy) in Israel (PO) (NCT02462265)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease) in Israel (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top